Characteristics of the 80 patients completing follow-up
. | No. of patients (%) according to randomization arm . | . | |
|---|---|---|---|
| Parameter . | IEmRNA n=41 . | Antigenemia n=39 . | |
| Median age (range) | 8 (1-23) | 8 (1-19) | |
| Sex (M/F) | 23/18 | 27/12 | |
| Diagnosis | |||
| AML | 8 (20) | 5 (13) | |
| ALL | 12 (29) | 13 (33) | |
| CML | 1 (2) | 0 | |
| JMML | 2 (5) | 2 (5) | |
| MDS | 5 (12) | 4 (10) | |
| Thalassemia | 6 (15) | 6 (15) | |
| NHL | 2 (5) | 0 | |
| Fanconi anemia | 1 (2) | 0 | |
| SAA | 2 (5) | 1 (3) | |
| DBA | 0 | 1 (3) | |
| Other* | 2 (5) | 7 (18) | |
| HCMV serology | |||
| R+/D- | 17 (41) | 10 (26) | |
| R-/D+ | 4 (10) | 7 (18) | |
| R+/D+ | 20 (49) | 22 (56) | |
| Donor type | |||
| Sibling | 23 (56) | 22 (56) | |
| UD | 18 (44) | 17 (44) | |
| Source of stem cell graft | |||
| Bone marrow | 33 (80) | 29 (74) | |
| Peripheral blood | 3 (7) | 6 (15) | |
| Cord blood | 5 (12) | 4 (12) | |
| Conditioning regimen | |||
| Chemotherapy based | 28 (68) | 27 (69) | |
| TBI based | 13 (32) | 13 (31) | |
| Grades II-IV GVHD | 16 (39) | 12 (31) | |
. | No. of patients (%) according to randomization arm . | . | |
|---|---|---|---|
| Parameter . | IEmRNA n=41 . | Antigenemia n=39 . | |
| Median age (range) | 8 (1-23) | 8 (1-19) | |
| Sex (M/F) | 23/18 | 27/12 | |
| Diagnosis | |||
| AML | 8 (20) | 5 (13) | |
| ALL | 12 (29) | 13 (33) | |
| CML | 1 (2) | 0 | |
| JMML | 2 (5) | 2 (5) | |
| MDS | 5 (12) | 4 (10) | |
| Thalassemia | 6 (15) | 6 (15) | |
| NHL | 2 (5) | 0 | |
| Fanconi anemia | 1 (2) | 0 | |
| SAA | 2 (5) | 1 (3) | |
| DBA | 0 | 1 (3) | |
| Other* | 2 (5) | 7 (18) | |
| HCMV serology | |||
| R+/D- | 17 (41) | 10 (26) | |
| R-/D+ | 4 (10) | 7 (18) | |
| R+/D+ | 20 (49) | 22 (56) | |
| Donor type | |||
| Sibling | 23 (56) | 22 (56) | |
| UD | 18 (44) | 17 (44) | |
| Source of stem cell graft | |||
| Bone marrow | 33 (80) | 29 (74) | |
| Peripheral blood | 3 (7) | 6 (15) | |
| Cord blood | 5 (12) | 4 (12) | |
| Conditioning regimen | |||
| Chemotherapy based | 28 (68) | 27 (69) | |
| TBI based | 13 (32) | 13 (31) | |
| Grades II-IV GVHD | 16 (39) | 12 (31) | |
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; JMML, juvenile myelo-monocytic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anemia; DBA, Diamond-Blackfan anemia; R, recipient; D, donor; UD, unrelated donor; TBI, total body irradiation.
Other includes 1 Hodgkin disease, 1 hemophagocytic lymphohistiocytosis, 1 chronic granulomatous disease, 2 sickle cell anemias, 1 Bernard-Soulier syndrome, 1 rhabdomyosarcoma, 1 Ewing sarcoma, and 1 mucopolysaccharidosis.